Conceptus Inc.

Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue

Retrieved on: 
Tuesday, October 10, 2023

The Company also announced preliminary revenue for the third quarter 2023.

Key Points: 
  • The Company also announced preliminary revenue for the third quarter 2023.
  • “Separately, we are very pleased with our record third quarter revenue as we continue to benefit from the focused commercial strategy that we implemented last year.
  • Total worldwide revenue for the third quarter of 2023 is anticipated to be approximately $17.6 million, representing growth of approximately 30% over the same quarter last year.
  • The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until the Company reports its full financial results for the quarter ended September 30, 2023.

TMRW Life Sciences Names Louis Villalba Chief Executive Officer

Retrieved on: 
Tuesday, June 27, 2023

NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointed Louis Villalba Chief Executive Officer effective immediately. Villalba has served as TMRW's Chief Business Officer since September 2022 and succeeds Tara Comonte who has led the company's successful growth for the last 2 years. Under Comonte's leadership the company scaled from 5 study partner clinics to 50 contracted commercial clinics and 20% market share, launched the state-of-the-art TMRW biorepository in New York City, and obtained FDA clearance for the company's next-generation platform for the safe management and storage of frozen eggs and embryos. Comonte will remain on the TMRW Board of Directors, a position she has held since 2018.

Key Points: 
  • NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointed Louis Villalba Chief Executive Officer effective immediately.
  • Villalba has served as TMRW's Chief Business Officer since September 2022 and succeeds Tara Comonte who has led the company's successful growth for the last 2 years.
  • Fertility clinics need and want new technologies to keep up with demand and deliver the best outcomes to their patients," said Lou Villalba, CEO of TMRW Life Sciences.
  • "We extend our congratulations to Louis Villalba on his appointment as the CEO of TMRW Life Sciences.

TMRW Life Sciences Names Louis Villalba Chief Executive Officer

Retrieved on: 
Tuesday, June 27, 2023

NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointed Louis Villalba Chief Executive Officer effective immediately. Villalba has served as TMRW's Chief Business Officer since September 2022 and succeeds Tara Comonte who has led the company's successful growth for the last 2 years. Under Comonte's leadership the company scaled from 5 study partner clinics to 50 contracted commercial clinics and 20% market share, launched the state-of-the-art TMRW biorepository in New York City, and obtained FDA clearance for the company's next-generation platform for the safe management and storage of frozen eggs and embryos. Comonte will remain on the TMRW Board of Directors, a position she has held since 2018.

Key Points: 
  • NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointed Louis Villalba Chief Executive Officer effective immediately.
  • Villalba has served as TMRW's Chief Business Officer since September 2022 and succeeds Tara Comonte who has led the company's successful growth for the last 2 years.
  • Fertility clinics need and want new technologies to keep up with demand and deliver the best outcomes to their patients," said Lou Villalba, CEO of TMRW Life Sciences.
  • "We extend our congratulations to Louis Villalba on his appointment as the CEO of TMRW Life Sciences.

Bayer reaffirms safety profile of Essure

Retrieved on: 
Friday, July 27, 2018

WHIPPANY, N.J., July 27, 2018 /PRNewswire/ -- Bayer is reminding women with Essure that the safety profile of Essure, the only Food and Drug Administration (FDA)-approved non-incisional form of permanent birth control, remains positive and unchanged.

Key Points: 
  • WHIPPANY, N.J., July 27, 2018 /PRNewswire/ -- Bayer is reminding women with Essure that the safety profile of Essure, the only Food and Drug Administration (FDA)-approved non-incisional form of permanent birth control, remains positive and unchanged.
  • There is no reliable scientific evidence to suggest that any new safety concerns exist with Essure.
  • Indeed, in 2015 FDA reviewed the safety data for Essure and did not identify new safety or efficacy concerns.
  • Bayer and the Bayer Cross are registered trademarks of Bayer.

Bayer reaffirms safety profile of Essure

Retrieved on: 
Friday, July 27, 2018

WHIPPANY, N.J., July 26, 2018 /PRNewswire/ --Bayer is reminding women with Essure that the safety profile of Essure, the only Food and Drug Administration (FDA)-approved non-incisional form of permanent birth control, remains positive and unchanged.

Key Points: 
  • WHIPPANY, N.J., July 26, 2018 /PRNewswire/ --Bayer is reminding women with Essure that the safety profile of Essure, the only Food and Drug Administration (FDA)-approved non-incisional form of permanent birth control, remains positive and unchanged.
  • There is no reliable scientific evidence to suggest that any new safety concerns exist with Essure.
  • Indeed, in 2015 FDA reviewed the safety data for Essure and did not identify new safety or efficacy concerns.
  • Bayer and the Bayer Cross are registered trademarks of Bayer.